Amylyx Pharmaceuticals (NASDAQ:AMLX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.82) by 20.73 percent. The company reported quarterly sales of $21.89 million which beat the analyst consensus estimate of $4.72 million by 363.67 percent.
Amylyx Pharmaceuticals Q4 EPS $(0.65) Beats $(0.82) Estimate, Sales $21.89
Amylyx Pharmaceuticals (NASDAQ:AMLX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.82) by 20.73 percent. The company reported quarterly sales of $21.89 million which
